Cordlife Group (SG:P8A) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cordlife Group Limited, a Singapore-based company specializing in cord blood and tissue banking, has accepted the latest directive from the Ministry of Health to resume operations with restrictions. The company will adhere to a modified license condition limiting them to process a maximum of 30 new cord blood units per month from infant donors, effective from 15 September 2024 until 13 January 2025.
For further insights into SG:P8A stock, check out TipRanks’ Stock Analysis page.
